Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Abstract Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the out...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2021-03-01
|
| Edice: | Experimental Hematology & Oncology |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s40164-021-00211-8 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|